Colton Groome Financial Advisors LLC bought a new stake in shares of Abbott Laboratories (NYSE: ABT – Get Rating) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,004 shares of the healthcare product maker’s stock, valued at approximately $ 356,000.
A number of other large investors have also bought and sold shares of ABT. Blue Bell Private Wealth Management LLC bought a new stake in Abbott Laboratories during the fourth quarter valued at about $ 30,000. Delos Wealth Advisors LLC increased its holdings in shares of Abbott Laboratories by 100.9% in the fourth quarter. Delos Wealth Advisors LLC now owns 231 shares of the healthcare product maker’s stock worth $ 33,000 after purchasing an additional 116 shares during the last quarter. Holloway Wealth Management LLC increased its holdings in shares of Abbott Laboratories by 175.0% in the first quarter. Holloway Wealth Management LLC now owns 275 shares of the healthcare product maker’s stock worth $ 33,000 after purchasing an additional 175 shares during the last quarter. Retirement Group LLC increased its holdings in shares of Abbott Laboratories by 1,125.0% in the fourth quarter. Retirement Group LLC now owns 245 shares of the healthcare product maker’s stock worth $ 34,000 after purchasing an additional 225 shares during the last quarter. Finally, Lumature Wealth Partners LLC increased its holdings in shares of Abbott Laboratories by 65.4% in the fourth quarter. Lumature Wealth Partners LLC now owns 301 shares of the healthcare product maker’s stock worth $ 42,000 after purchasing an additional 119 shares during the last quarter. 73.46% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have weighed in on ABT. Morgan Stanley reduced their price objective on Abbott Laboratories from $ 151.00 to $ 145.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 7th. Royal Bank of Canada lowered their price target on Abbott Laboratories from $ 146.00 to $ 143.00 and set an “outperform” rating for the company in a report on Thursday, April 21st. Citigroup reduced their price objective on shares of Abbott Laboratories from $ 154.00 to $ 125.00 and set a “na” rating for the company in a research note on Tuesday, May 17th. BTIG Research reduced their price objective on shares of Abbott Laboratories from $ 140.00 to $ 130.00 and set a “buy” rating for the company in a research note on Friday. Finally, Raymond James reduced their price objective on shares of Abbott Laboratories from $ 143.00 to $ 135.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $ 139.64.
In other news, SVP Randel William Woodgrift sold 24,000 shares of Abbott Laboratories stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $ 113.00, for a total transaction of $ 2,712,000.00. Following the completion of the sale, the senior vice president now directly owns 47,854 shares of the company stock, valued at approximately $ 5,407,502. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Daniel J. Starks sold 50,000 shares of Abbott Laboratories stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $ 113.22, for a total transaction of $ 5,661,000.00. Following the sale, the director now directly owns 6,973,500 shares of the company stock, valued at $ 789,539,670. The disclosure for this sale can be found here. 0.52% of the stock is owned by company insiders.
ABT stock opened at $ 109.11 on Monday. The company 50-day simple moving average is $ 112.55 and its 200-day simple moving average is $ 121.14. The company has a quick ratio of 1.40, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. Abbott Laboratories has a 52-week low of $ 101.24 and a 52-week high of $ 142.60. The firm has a market cap of $ 191.05 billion, a P / E ratio of 25.39, a PEG ratio of 3.95 and a beta of 0.73.
Abbott Laboratories (NYSE: ABT – Get Rating) last issued its quarterly earnings results on Wednesday, April 20th. The healthcare product maker reported $ 1.73 earnings per share for the quarter, beating analysts’ consensus estimates of $ 1.47 by $ 0.26. The firm had revenue of $ 11.90 billion for the quarter, compared to analyst estimates of $ 11 billion. Abbott Laboratories had a net margin of 17.35% and a return on equity of 28.72%. Abbott Laboratories’ s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company posted $ 1.32 EPS. On average, analysts anticipate that Abbott Laboratories will post 4.84 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be issued a dividend of $ 0.47 per share. The ex-dividend date is Thursday, July 14th. This represents a $ 1.88 dividend on an annualized basis and a dividend yield of 1.72%. Abbott Laboratories’s dividend payout ratio is currently 43.62%.
Abbott Laboratories Profile: (Get Rating)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Recommended Stories:
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE: ABT – Get Rating).
Receive News & Ratings for Abbott Laboratories Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.
.